Evidence map›Paper›PMID 8887626›Full record

ArticleMolecular and cellular biology1996

Stimulation of C2C12 myoblast growth by basic fibroblast growth factor and insulin-like growth factor 1 can occur via mitogen-activated protein kinase-dependent and -independent pathways.

D J Milasincic, M R Calera, S R Farmer, P F Pilch

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 121 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Insulin-like growth factor 1 physiology: lessons from mouse models.Endocrinology and metabolism clinics of North America · 2012
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. MAP kinase phosphatase-1 deficiency impairs skeletal muscle regeneration and exacerbates muscular dystrophy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

D J MilasincicDepartment of Biochemistry, Boston University Medical School, Massachusetts 02118, USA.
M R Calera
S R Farmer
P F Pilch
Boston University · US

Funding

REGULATION OF MYOGENESIS DURING DEVELOPMENTP01DK044269 · NIDDK · BOSTON UNIVERSITY MEDICAL CAMPUS · PI PILCH, PAUL F · 1992 to 1996
–
REGENERATING LIVER AND HEPATIC DIFFERENTIATIONR01DK045048 · NIDDK · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FARMER, STEPHEN ROBERT · 1993 to 1995
–
NIDDK NIH HHS DK-44269NIDDK NIH HHS DK45048
6 · The paper itself

Abstract

It is now well-recognized that the mitogen-activated protein (MAP) kinase cascade facilitates signaling from an activated tyrosine kinase receptor to the nucleus. In fact, an increasing number of extracellular effectors have been reported to activate the MAP kinase cascade, with a significant number of cellular responses attributed to this activation. We set out to explore how two extracellular effectors, basic fibroblast growth factor (bFGF) and insulin-like growth factor 1 (IGF-1), which have both been reported to activate MAP kinase, generate quite distinct cellular responses in C2C12 myoblasts. We demonstrate here that bFGF, which is both a potent mitogen and inhibitor of myogenic differentiation, is a strong MAP kinase agonist. By contrast, IGF-1, which is equally mitogenic for C2C12 cells but ultimately enhances the differentiated phenotype, is a weak activator of the MAP kinase cascade. We further demonstrate that IGF-1 is a potent activator of both insulin receptor substrate IRS-1 tyrosyl phosphorylation and association of IRS-1 with activated phosphatidylinositol 3-kinase (PI 3-kinase). Finally, use of the specific MAP kinase kinase inhibitor, PD098059, and wortmannin, a PI 3-kinase inhibitor, suggests the existence of an IGF-1-induced, MAP kinase-independent signaling event which contributes to the mitogenic response of this factor, whereas bFGF-induced mitogenesis appears to strongly correlate with activation of the MAP kinase cascade.

Indexed as

Signal TransductionAndrostadienesAnimalsCalcium-Calmodulin-Dependent Protein KinasesCell DifferentiationCell DivisionCell LineDNAEnzyme ActivationEnzyme InhibitorsFibroblast Growth Factor 2FlavonoidsHumansInsulin-Like Growth Factor IInsulin Receptor Substrate ProteinsKinetics2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-oneAndrostadienesCalcium-Calmodulin-Dependent Protein KinasesDNAEnzyme InhibitorsFibroblast Growth Factor 2FlavonoidsInsulin-Like Growth Factor IInsulin Receptor Substrate ProteinsIRS1 protein, humanIrs1 protein, mouseMitogen-Activated Protein Kinase KinasesPhosphatidylinositol 3-KinasesPhosphoproteinsPhosphotransferases (Alcohol Group Acceptor)PhosphotyrosineProtein Kinase InhibitorsRecombinant ProteinsWortmannin

Identifiers

PMID8887626
PMCPMC231599
OpenAlexW2141608854

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.